LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts

LAVA Therapeutics N.V. (NASDAQ:LVTX) has received an average rating of “Reduce” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a hold rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $2.6850.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of LAVA Therapeutics in a report on Wednesday, October 8th.

LAVA Therapeutics Stock Performance

Shares of LVTX stock opened at $1.74 on Monday. The firm has a market cap of $45.77 million, a P/E ratio of -2.02 and a beta of 0.50. The business’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.50. LAVA Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $2.00.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). As a group, equities analysts predict that LAVA Therapeutics will post -1.13 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Versant Venture Capital Vi, L. sold 532,870 shares of LAVA Therapeutics stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $1.40, for a total transaction of $746,018.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Gilde Healthcare Cooperatieve sold 1,181,131 shares of the business’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $1.47, for a total transaction of $1,736,262.57. Following the sale, the insider directly owned 2,947,781 shares in the company, valued at $4,333,238.07. The trade was a 28.61% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,861,226 shares of company stock worth $9,944,164. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LAVA Therapeutics

Several large investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in shares of LAVA Therapeutics in the 1st quarter worth approximately $31,000. Lepercq De Neuflize Asset Management LLC bought a new position in shares of LAVA Therapeutics in the first quarter worth approximately $29,000. BML Capital Management LLC lifted its stake in shares of LAVA Therapeutics by 0.5% in the second quarter. BML Capital Management LLC now owns 1,970,610 shares of the company’s stock worth $2,601,000 after buying an additional 10,000 shares in the last quarter. Rangeley Capital LLC purchased a new stake in shares of LAVA Therapeutics during the second quarter valued at approximately $36,000. Finally, Shay Capital LLC bought a new stake in shares of LAVA Therapeutics during the third quarter valued at approximately $3,976,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.